59 This study underlines the role of proinflammatory and/or neurotrophins in the development of painful degenerated IVDs
1 Rybelsus delivers lower exposure to semaglutide than the injectable form tested in that trial, meaning the difference in practice is likely even larger
Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rnne J, Alanentalo T, Baquero AF, Buckley ST, Farkas E, Fekete C, Frederiksen KS
ACS Med Chem Lett 8:989991
Regular follow-ups and monitoring as part of the Semaglutide treatment program help in maintaining these health benefits over time, ensuring patients do not just see temporary changes but experience lasting health improvements
In the REDEFINE 1 phase 3 trial, cagrilintide 2.4 mg monotherapy produced an average body weight reduction of 11.8% over 68 weeks